Chimeric Polypeptide Vaccine Toxoplasma gondii Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Toxoplasma gondii infections, particularly the latent cyst form, are inadequate due to toxicity issues with existing antiparasitic medicines and the inability to effectively eliminate the parasite, highlighting a need for a safe and effective vaccine.
Innovation Solution
Development of a chimeric polypeptide comprising specific CD8+ and CD4+ epitopes, combined with a recombinant expression vector and adjuvants like GLA-SE, to stimulate a robust immune response and limit infection, including the use of self-assembling protein nanoparticles and self-replicating RNA nanoparticles to present antigenic epitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiparasitic medicines such as sulfadiazine and pyrimethamine are used to treat T. gondii infection, then the tachyzoite form is effectively controlled, but toxicity and hypersensitivity occur and the latent cyst form is not eliminated
Solution Approach 1:
The patent extracts and isolates specific protective epitopes (such as SAG1, SAG2, GRA6, ROP16) from the T. gondii parasite and uses them as vaccine antigens. This extraction approach allows the vaccine to target essential protective antigens without including other harmful or toxic components of the parasite, thereby providing protection while avoiding the toxicity associated with whole-parasite or crude extract treatments
Solution Approach 2:
The patent applies local quality by selecting and combining specific epitopes from different T. gondii proteins that are expressed at different stages of the parasite lifecycle (tachyzoite and bradyzoite forms). This targeted approach ensures that the vaccine elicits immune responses against specific protective antigens while avoiding non-protective or harmful components, thereby achieving stage-specific protection without systemic toxicity
2Adaptability or versatility
If a vaccine is designed to protect against both acute and chronic T. gondii infection, then comprehensive immunity is achieved, but the vaccine complexity increases due to need for multiple epitopes
Solution Approach 1:
The patent merges multiple epitopes from different T. gondii proteins (SAG1, SAG2, GRA6, ROP16) into a single chimeric polypeptide construct. This consolidation allows the vaccine to target both acute (tachyzoite) and chronic (bradyzoite) infection stages through one integrated antigen, simplifying vaccine administration while maintaining comprehensive protection against multiple parasite forms
Solution Approach 2:
The patent designs the chimeric polypeptide vaccine to perform multiple functions simultaneously: it presents epitopes from both tachyzoite and bradyzoite stages, activates both CD4+ and CD8+ T cell responses, and provides protection against both acute and chronic infection. This multi-functionality is achieved by strategically selecting and combining epitopes that cover the entire parasite lifecycle in a single vaccine construct
Data Source
AI summary
Disclosed herein are polynucleotides encoding multi-epitope polypeptides and assemblies thereof, and their use for treating or limiting Toxoplasma gondii infection.